Search the database for deliberate release of GM medicinal products
Displaying 1 - 2 of 2
| EU record number | Title | Company / Sponsor | Treated organism | Genetic modification |
|---|---|---|---|---|
| Only notified under the "contained use" procedure. Dossier submitted on 22/05/2023. | A randomized, open-label, Phase 2 study evaluating lymphodepletion with fludarabine (F), cyclophosphamide (C), and ALLO-647 (A) vs FC alone, in subjects with R/R LBCL receiving ALLO-501A allogeneic CAR T cell therapy | Allogene therapeutics | Humans | CD19 CAR + knockouts CD52 and TRAC via TALEN technology |
| Only notified under the "contained use" procedure. Dossier submitted on 26/03/1998. | Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esopha | Pasteur Mérieux Connaught | Humans | HLA-A1 restricted CTL epitope of MAGE-1 and MAGE-3 genes |